NewsSignals AI analysis·ShareCast·Oct 30, 2026

Astrazeneca posts solid Q3 numbers, NatWest Q3 profits slip

Grade Abullish AI signal$AZN$NWG

AstraZeneca delivered a strong Q3 earnings beat, with revenue rising 7% to $16.21 billion and core EPS climbing 17% to $2.79, while NatWest reported weaker quarterly profits. AstraZeneca's nine-month revenue reached $46.88 billion, with operating profits up 10%, while NatWest's attributable profits declined to £1.5 billion from £1.6 billion a year earlier. AstraZeneca's earnings momentum and pipeline progress could support its shares, while weaker NatWest profitability may pressure investor sentiment toward the bank.

Bullish strength: 70/100

AstraZeneca delivered another solid earnings beat.
Q3 revenue increased 7% to $16.21 billion.
Core earnings per share rose 17% to $2.79.
Nine-month operating profits increased 10% to $11.80 billion.
Late-stage drug pipeline momentum strengthened.

Bearish strength: 30/100

NatWest Q3 attributable profits declined to £1.5 billion from £1.6 billion.
NatWest return on tangible equity slipped to 21.6% from 22.3%.
NatWest earnings per share fell to 19.3p from 19.8p.

This is automated NewsSignals analysis of third-party reporting, not independent original reporting or investment advice. AI scores are not price predictions.

Read the original source ↗

← Browse more news analysis

Trade on MEXC

More recent source-attributed AI analysis.

US Fintech Weekly: Fiserv Bounces Post-Earnings, Crypto Brokers Suffer, And Federal Agencies Prepare Innovation Guidelines

Fiserv shares surged nearly 13% after earnings, while crypto-linked stocks Robinhood and Coinbase headed for a sixth consecutive weekly decline amid Bitcoin weakness and growing regulatory uncertainty. Fiserv benefited from an earnings beat and a new $500 million share buyback authorization, while six federal agencies are preparing fintech innovation guidelines ahead of a November 15 deadline. Stronger regulatory oversight under Democratic congressional control could pressure crypto platforms, although continued institutional integration may limit the sector's downside.

Corn, soybean futures sag under weight of big US crops

US corn and soybean futures fell to multi-month lows as large domestic harvests continued to weigh on prices, with corn approaching a four-month low and soybeans hitting a 2-1/2-month low. December corn closed down 4.25 cents at $4.40 per bushel, while January soybeans dropped 14 cents to $11.88¼; analysts expect the USDA to report a record-large soybean harvest next week. Rising US crop supplies could maintain downward pressure on corn and soybean prices, while wheat may remain sensitive to developments surrounding Black Sea shipping access.

Healthcare, Insurers 'Best Places to Hide' on AI Cycle Unwind Worries — Market Talk

UBS identifies Australian healthcare and insurance stocks as potential defensive havens if concerns about an unwinding AI trade intensify. The sectors have shown negative share-price correlations with the PHLX Semiconductor Index and Global DC Index, while UBS maintains overweight recommendations on both. Their relative independence from the AI cycle could provide portfolio protection if technology stocks face further pressure.

Gold climbs to two-week high as dollar, yields weaken

Gold climbed 1% to $4,102.50 per ounce, reaching its highest settlement since October 21 as a weaker US dollar and falling Treasury yields boosted demand. The 10-year Treasury yield dropped 5.5 basis points to 4.836%, while silver gained 0.2% to $52.233 per ounce. Gold could face renewed selling pressure if Friday's US jobs report strengthens expectations for a December Fed rate hike, despite improving near-term momentum.